Chengdu Easton Biopharmaceuticals Co., Ltd. (SHA:688513)
China
· Delayed Price · Currency is CNY 57.21
-0.74 (-1.28%)
Mar 9, 2026, 3:00 PM CST
Chengdu Easton Biopharmaceuticals Company Description
Chengdu Easton Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, and commercialization of pharmaceutical products.
The company provides finished dosage forms comprising capsules, tablets, and injections, as well as active pharmaceutical ingredients (API).
It also offers API products, such as Apixaban for cardiovascular applications; Apualutamide, Bosutinib, Dacomitinib, Ibrutinib, Nilotinib HCL, Nintedanib, Relugolix, and Ruxolitinib Phosphate for oncological applications; Bricaracetam and Lacosamide for neurological and psychiatric applications; and Empagliflozin for anti-diabetic applications.
The company was founded in 2009 and is based in Chengdu, China.
Chengdu Easton Biopharmaceuticals Co., Ltd.
| Country | China |
| Founded | 2009 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,522 |
| CEO | Mingxu Yuan |
Contact Details
Address: No. 8, Ankang Road Chengdu, 610200 China | |
| Phone | 86 28 8782 7191 |
| Website | eastonpharma.cn |
Stock Details
| Ticker Symbol | 688513 |
| Exchange | Shanghai Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE100004397 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Mingxu Yuan | GM and Director |
| Xiao Qin Bo | Chief Financial Officer, Accounting Supervisor and Director |
| Daming Zhang | Deputy GM and Director |
| Shuyun Li | Board Secretary |
| Zheng Pin Guan | Deputy GM and Core Technician |
| Xingyao Song | Deputy General Manager |
| Avinash Ramkisan Mane | Chief Scientist of Formulation Research Department and Core Technician |
| Haibin Guo | Manager of Formulation Research Department and Core Technician |